Mangoceuticals (MGRX) Invested Capital (2022 - 2026)

Mangoceuticals has disclosed Invested Capital across 5 years of filings, most recently posting $12.6 million for Q2 2026.

• In Q2 2026, Invested Capital fell 36.1% year-over-year to $12.6 million; the TTM figure through Jun 2026 stood at $12.6 million (down 36.1% YoY), while the FY2024 annual figure was $14.1 million, up 1719.29% from the prior year.
• Invested Capital came in at $12.6 million for Q2 2026 at Mangoceuticals, down from $15.8 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $20.3 million in Q1 2025 to a low of -$870968.0 in Q1 2024.
• Average Invested Capital over 5 years is $11.1 million, with a median of $14.0 million recorded in 2024.
• Year-over-year, Invested Capital soared 2425.08% in 2025 and sank 36.1% in 2026.
• Over 5 years, Invested Capital stood at $781489.0 in 2022, then slipped by 0.86% to $774754.0 in 2023, then soared by 1719.29% to $14.1 million in 2024, then rose by 12.3% to $15.8 million in 2025, then fell by 20.3% to $12.6 million in 2026.
• Per Business Quant data, the three most recent Invested Capital figures were $12.6 million in Q2 2026, $15.8 million in Q3 2025, and $19.7 million in Q2 2025.